NRC Health (NRC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

NRC Health

NasdaqGS•Healthcare•Health Information Services

$21.53+0.28(0.01%)Market closed

Market Cap

$452.51M

P/E

77.2x

P/S

3.2x

P/B

69.1x

NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.

How this company scores

AverageMetricSide Score: 47/100

Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (4/25).

Profitability14/25

Growth5/25

Balance Sheet & Red Flags4/25

Cash & Earnings Quality24/25

Strengths

Rising free cash flowHigh ROECash-backed earningsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 77.2x5y range 12.1x – 77.2x

Currently above its 20-quarter median.

P/S · 3.2x5y range 2.0x – 7.6x

Currently below its 20-quarter median.

P/B · 69.1x5y range 9.9x – 69.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 45.9% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $452.51M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $140.00M
Q. Revenue: $35.39M
TTM EBITDA: $23.37M
TTM Op. Income: $14.74M
Q. Op. Income: $-3.24M
TTM Net Income: $5.86M
Q. Net Income: $-3.28M
EPS: $-0.15
Shares Out.: $22.01M

$140.00M in TTM revenue declined 0.2% YoY, reaching $35.39M last quarter. TTM EBITDA of $23.37M and TTM operating income of $14.74M show growth is flowing through to the bottom line. TTM net income of $5.86M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -3.2%
Op. Margin: -9.1%
Net Margin: -9.3%

Op. margin of -9.1% is down 13.8% YoY — costs are rising relative to revenue. Net margin at -9.3% Over the past year, operating margin is down 296% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 77.2x
P/S Ratio: 3.2x
P/B Ratio: 69.1x

At 77.2x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.2x and P/B of 69.1x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $136.15M
Cash: $3.33M
Long-Term Debt: $86.01M
Book Value: $6.55M
D/E Ratio: 13.1
Debt/EBITDA: N/A

With $136.15M in assets and $86.01M in long-term debt, D/E is 13.1and book value is $6.55M — elevated leverage, meaning significant financial risk in a downturn. Across the last 8 quarters, debt/equity has risen for 7 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.39M
TTM Free Cash Flow: $21.64M
FCF Margin: 15.5%
FCF / Net Income: 3.7

TTM FCF of $21.64M on $1.39M in operating cash flow. The FCF / Net Income ratio of 3.7x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.